Business
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Innovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"Innovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction\nNEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that enrollment has completed in the randomized, double-blind Phase 2 SEQUEL study (COG0202, NCT04735536) of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess differences in synaptic function in CT1812- versus placebo-treated participants using quantitative electroencephalogram (qEEG) to measure theta waves, the type of brain activity most commonly associated with processing information and memory formation. Topline results from SEQUEL are expected mid-2023. There is substantial evidence that Aβ oligomers have the potential to impair synaptic and neuronal activity. The use of qEEG allows this decline in synaptic activity to be observed as a change in neural oscillation –the natural ebb and flow of electrical activity that is associated with normal communication between neurons. As a fast and cost-effective method of measuring the electrical activity of the brain, qEEG may represent a non-invasive biomarker of Alzheimer's disease progression and treatment effect. “We have previously shown that qEEG can detect changes in whole-brain electrical patterns as well as regional patterns associated with the coordinated transfer of information that is required for executive function in Alzheimer’s disease,” explained Everard (Jort) Vijverberg, M.D., Ph.D., a neurologist and senior researcher at the Amsterdam University Medical Centers and principal investigator in SEQUEL. “In the SEQUEL study, we use qEEG as an experimental outcome measure to determine the effect of CT1812 on Alzheimer disease processes in the brain. We expect results will show that untreated Alzheimer’s patients experience an increase in theta power and a decrease of the alpha band, which may indicate a slowing of brain activity.” CT1812 is an oral small molecule designed to bind selectively to the sigma-2 (σ-2) receptor and displace beta amyloid (Aβ) oligomers from synapses. Soluble Aβ oligomers and protofibrils have been recognized as the most neurotoxic form of amyloid in the literature and recently...